Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Gain Therapeutics ( (GANX) ) has shared an announcement.
On February 6, 2025, Gain Therapeutics announced the advancement of their clinical development for GT-02287, a promising therapy for Parkinson’s disease. Following a successful Phase 1 study, they have begun a Phase 1b trial in Australia, aiming to demonstrate its disease-modifying effects. The company plans to continue its research and potentially expand trials, leveraging positive feedback from the FDA and maintaining strong financial health to support operations.
More about Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the development of next-generation allosteric therapies, with a lead drug candidate, GT-02287, targeting Parkinson’s disease. The company’s unique approach utilizes the Magellan™ platform to discover novel small molecule modulators for neurodegenerative diseases, rare genetic disorders, and oncology.
YTD Price Performance: 5.17%
Average Trading Volume: 229,570
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $64.72M
Find detailed analytics on GANX stock on TipRanks’ Stock Analysis page.
